Samsung C&T’s efforts to improve profitability in addition to performance gains at subsidiary BioLogics have led to an increase in quarter-over-quarter (QoQ) operating profit, despite a drop in year-over-year (YoY) revenue due to COVID-19 and completion of large-scale projects, etc. KRW 7.223tn in revenue and KRW 238bn in operating profit,

Overall Performance Revenue: KRW 6.960tn, year-over-year (yoy) decrease by 397bn (5.4%) from 7.357tn in 1Q19 Operating Profit: KRW 147bn, yoy increase by 42bn (40.0%) from 105bn in 1Q19 Revenue fell as trading volume and domestic consumption decreased amid the COVID-19 situation, and as construction projects undertaken by the company reached

Samsung C&T held its 56th annual general shareholders’ meeting (AGM) in Seoul on March 20 for the fiscal year of 2019, with 73.4% of voting shares represented at the company’s headquarters in Seoul. The agenda included the approval of the full-year financial statement, appointment of board members, and cancellation of

Samsung C&T’s Board of Directors on February 26 approved a series of measures aimed at enhancing shareholder value and corporate governance: – New shareholder return policy (FY20-FY22 dividend policy, treasury share cancellation) – Measures to facilitate board-centric governance ① Appointment of 3 independent director candidates ② Strengthening of role and

Samsung C&T again ranked among Korea’s All-Star companies, according to 2020 Korea’s Most Admired Companies survey result announced by Korea Management Association Consulting (KMAC) on Feb. 25. The All-Star list was made up of the top 30 Korean firms deemed excellent in competitiveness and values through an overall company evaluation.

Samsung C&T posted KRW 30.8tn in revenue and KRW 867bn in operating profit for FY 2019. It also posted KRW 7.7tn in Q4 2019 revenue and KRW 325bn in Q4 2019 operating profit, continuing the upward trend in quarterly performance. Efforts to improve financial structure, leading to a reduction total